View Printer-Friendly PDF

A Drug Development & Outsourcing Profile

Aquinox Pharmaceuticals (Canada) Inc.

450-887 Great Northern Way
Vancouver BC  V5T 4T5
Canada

  • Tel: 604-629-9223
  • Fax: 778-331-4486
  • Mgmt:
  • COO: Tom MacRury
  • R&D:
  • Licng:
  • Est: 2006 - Public
  • Rev: $0–1 M
  • Staff: 10–50
  • Therapeutics-Human
  • Anti-inflammatory
  • Clinical Research
  • COPD
  • BladderPain Syndrome
  • InterstitialCystitis
  • Drug Development
  • Discovery Screening
  • Immunology
  • Respiratory
  • Dermatology
  • Urology

Aquinox is developing novel, small molecule therapeutics targeting SH2-containing inositol-5'-phosphatase 1 ("SHIP1") for the treatment of inflammatory disease and cancer. Its lead product candidate, AQX-1125, has demonstrated broad anti-inflammatory activity in vitro and in vivo, and has successfully completed three clinical trials with over 100 patients enrolled to date. Aquinox is currently investigating AQX-1125 in two Phase 2 clinical trials, one for exacerbations related to COPD, and one for BPS/IC.

Mfg: No   Labs: No

AQXP

0.0249